• SAMUEL JACOB BUNU Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.
  • DIEPREYE ERE Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.
  • OYEINTONBARA MIEDIEGHA Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria.


Individuals respond to the same medications in diverse manners. Polymorphism in drug-metabolizing enzymes plays a very important role in interindividual variations in drug medical care. Hence, the aim was to review reported cases of genetic polymorphisms among the antiretrovirals, especially efavirenz, a non-nucleoside reverse transcriptase inhibitor, used in the management of human immunodeficiency virus infection/acquired immune deficiency syndrome, which is metabolized primarily by the CYP2B6 enzyme. Several previous publications on genetic polymorphism associated with the antiretrovirals of patients on highly active antiretroviral therapy were selected and carefully reviewed to evaluate their correlation and or conflict of interest among different authors. The existence of polymorphisms on the CYP2B6 gene that encodes for expression of the enzyme, among other factors responsible for efavirenz metabolism, is a significant determinant of inter-individual variability in pharmacokinetics and pharmacodynamic response to the drug used in clinical practice. Furthermore, plasma levels of efavirenz and phenotypic difference were observed, are contributing factors as to the rate of antiretroviral adverse drug reactions. Following the review, studies showed similar outcomes relating to efavirenz pharmacokinetics and polymorphism; hence, patients that display genetic polymorphism on efavirenz may likely develop the same on other therapeutic agents metabolized by the CYP450 enzymes or other polymorphic enzymes.

Keywords: Polymorphism, HIV/AIDS, CYP450, Pharmacogenetics, Pharmacokinetics


1. Sepkowitz KA. AIDS--the first 20 years. N Engl J Med 2001;344:1764-72.
2. Krämer A, Kretzschmar M, Krickeberg K. Modern Infectious Disease Epidemiology Concepts, Methods, Mathematical Models, and Public Health. New York: Springer; 2010. p. 88.
3. World Health Organization. Guideline on when to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV. Geneva: World Health Organization; 2015. p. 13.
4. World Health Organization. Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-related Disease in Adults and Children. Geneva: World Health Organization; 2007. p. 6-16.
5. UNAIDS. Fact Sheet-latest Statistics on the Status of the AIDS Epidemic UNAIDS. Available from: [Last accessed on 2017 July 21].
6. GAIDST. Global HIV and AIDS Statistics (GAIDST). AVERT; 2015. Available from: [Last accessed on 2017 July 10].
7. Mandell G, Bennett J, Dolan R. Principles and Practice of Infectious Diseases. Ch. 118, 121, 169. London, United Kingdom: Churchill Livingstone; 2010.
8. Vogel M, Schwarze-Zander C, Wasmuth JC, Spengler U, Sauerbruch T, Rockstroh JK. The treatment of patients with HIV. Dtsch Arztebl Int 2010;107:507-15.
9. Mittal R, Rath S, Vemuganti GK. Ocular surface squamous neoplasia-review of etiopathogenesis and an update on clinico-pathological diagnosis. Saudi J Ophthalmol 2013;27:177-86.
10. Rom WN, Markowitz SB. Environmental and Occupational Medicine. 4th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2007. p. 745.
11. PMCT. Preventing Mother-to-child Transmission (PMCT) of HIV; 2017. Available from: [Last accessed on 2017 Dec 08].
12. Coutsoudis A, Kwaan L, Thomson M. Prevention of vertical transmission of HIV-1 in resource-limited settings. Expert Rev Anti Infect Ther 2010;8:1163-75.
13. World Health Organization. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach; 2003. Available from: arvrevision2003en.
14. Oluka MN, Matimba A, Okalebo FA, Osanjo GO, Guantai AN, Masimirembwa CM. Characterization of inter-ethnic genetic variability of CYP2D6, CYP2C19, CYP2B6, NAT2 and GSTs in the Bantu and Nilotic populations of Kenya and implications for the chemotherapy of infectious diseases. Afr J Pharmacol Ther 2014;3:38-46.
15. UNAIDS. New HIV Infections Among Children have Been Reduced by 50% or more in Seven Countries in Sub-Saharan Africa. Geneva: UNAIDS; 2013.
16. Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: Raising the barrier to resistance. Antiviral Res 2010;85:59-74.
17. Perelson AS, Neumann AU, Markowitz M, Leonard JM. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
18. Smyth RP, Davenport MP, Mak J. The origin of genetic diversity in HIV-1. Virus Res 2012;169:415-29.
19. GUAA. Guidelines for the Use of Antiretroviral Agents (GUAA) in HIV-1-infected Adults and Adolescents. Washington, D.C, United States: US Department of Health and Human Services; 2015.
20. Henkel J. Attacking AIDS with a “Cocktail” Therapy. FDA Consumer. United States: Food and Drug Administration, US Department of Health and Human Services; 2009.
21. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10:412-26.
22. Smith BT. Concepts in Immunology and Immunotherapeutics. 4th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2008. p. 143.
23. Grant RW. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21.
24. Weinberg RA. The Biology of Cancer. 2nd ed. United Kingdom: Garland Science, Taylor & Francis Group; 2013.
25. Borges JB. Polymorphisms in genes encoding metalloproteinase 9 and lymphotoxin-alpha can influence warfarin treatment. J Pharm 2015;6:143.
26. Ishii M. A cyclooxygenase 2 gene polymorphism is a risk factor for the complication of medication overuse headaches in patients with migraines. J Neurol Disord 2015;3:206.
27. Rod A. ESR1 and FSHR gene polymorphisms influence ovarian response to FSH in poor responder women with normal FSH levels. Endocrinol Metab Synd 2014;4:141.
28. Charles BH, Reeders JW, Goodman PC. Radiology of AIDS. Berlin: Springer; 2001. p. 19.
29. Younes AK. Lack of association between catalase gene polymorphism and susceptibility to vitiligo in an Egyptian population. Pigment Disord 2014;3:124.
30. Shajithanoop S. The serotonin receptor 2a (Ser 2a) gene polymorphism and its association with obesity and dyslipidemia in semi-urban subjects of Coimbatore, South India. J Obes Weight Loss Ther 2013;3:178.
31. Zar T. Focal segmental glomerulosclerosis associated seronegative antiphospholipid syndrome. J Nephrol Therapeut 2012;2:123.
32. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011;1:a006841.
33. Wasim M, Fakhar N. Leptin gene mutations in morbidly obese and severely lean individuals from Punjab, Pakistan. J Obes Weight Loss Ther 2014;4:233.
34. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300.
35. Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 1999;48:528-35.
36. Elliott T. Lecture Notes: Medical Microbiology and Infection. United States: John Wiley & Sons; 2012. p. 273.
37. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y. Involvement of CYP2B6 in the n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001;29:887-890.
38. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001;51:281-5.
39. Sandhya P. Self-nano emulsifying drug delivery system of efavirenz: Formulation, in vitro evaluation and characterization. Asian J Pharm Clin Res 2019;12:217-26.
40. Barret J, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002;40:507-19.
41. Marzolini C, Telenti A, Descosterd LA, Grueb G, Biolazz J, Buclin T. Efavirenz plasma level can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001;5:71-5.
42. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2015;15:1-5.
43. Ebeshi UB, Oluseye OB, Collen MM. Cytochrome P450 2D6 (CYP2D6) genotype and phenotype determination in the Nigeria population. Asian J Pharm Health Sci 2011;1:47-54.
44. Scibona P, Vazquez C, Cajal AR, Argibay PF, Belloso WH. Prevalence of CYP2B6 polymorphisms in Argentinians: The role of genetic testing. Genet Mol Res 2015;14:16594-9.
45. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003;73:20-30.
46. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 2013;4:24.
47. Pingoud A, Alves J, Geiger R. Restriction enzymes Enzymes of molecular biology. In: Burrell M, editor. Methods of Molecular Biology. Ch. 8. Totowa, NJ: Humana Press; 1993. pp. 107-200.
48. Tandel L, Sonone R, Jain V. A novel reverse-phase high-performance liquid chromatographic method for simultaneous estimation of aloe-emodin and piperine in the ayurvedic formulation. Asian J Pharm Clin Res 2020;13:51-4.
49. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunk WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in populations of Africa and Asian origin: Allele frequencies, novel functional variations and possible implications for anti-HIV therapy with efavirenz. Pharmacogent Genomics 2005;15:861-73.
50. Filiptsova O, Kobets M, Kobets J, Naboka O, Koiro O, Ochkur A, et al. Distribution of CYP2B6 516G/T pharmacogentically important polymorphism in the Ukrainian population. Saudi Pharm J 2018;26:651-5.
51. Onoja AJ, Nasidi A, Abu A, Odama L, Braimoh G, Inyang US, et al. HIV-1 Seroprevalence and Incidence Among Commercial Sex Workers in Three Major Nigerian Cities. Bangkok Thailand: International Conference on AIDS, 15(WePeC6218); 2004.
52. Mukonzo JK, Röshammar D, Waako P, Andersson M, FukasawaT, Milani L, et al. A novel polymorphism in the ABCB1 gene, CYP2B6*6 and sex predicts single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009;68:690-9.
53. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, et al. Long-term efavirenzautoinduction and itseffect on plasma exposure in HIV patients. ClinPharmacolTher 2010;88:676-684.
54. Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two Sub-Saharan Africa populations. PLoS One 2013;8:e67946.
55. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 516G>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64:357-65.
51 Views | 80 Downloads
How to Cite
JACOB BUNU, S., D. ERE, and O. MIEDIEGHA. “CLINICAL RELEVANCE OF EFAVIRENZ PHARMACOKINETICS AND PHARMACOGENETICS IN HIV/AIDS THERAPY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 6, Apr. 2020, pp. 26-30, doi:10.22159/ajpcr.2020.v13i6.37405.
Review Article(s)